銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城

The WeWork India IPO enters its second day of subscription today, 6 October 2025. Till the end of day 1, the IPO received a muted response and got a total subscription of 0.04 times. The bidding window is scheduled to close on October 3, 2025.?
The WeWork India IPO is a book-building issue of ?3000 crore, consisting entirely of an offer for sale of 4.63 crore shares. The price band is set between ?615 and ?648 per share. The basis of allotment will be finalised by October 8, 2025, and the tentative listing date on NSE and BSE is October 10, 2025.?
The book-running lead managers for the IPO are JM Financial Limited, ICICI Securities Limited, Jefferies India Private Limited, Kotak Mahindra Capital Company Limited, 360 ONE WAM Limited, while Bigshare Services Private Limited serves as the registrar for the issue.
[6-October-2025 17:00:00]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.09 |
|
Non-Institutional Investors |
0.06 |
|
Retail Individual Investors (RIIs) |
0.37 |
|
Employees |
1.44 |
|
Total |
0.13 |
[3-October-2025 17:00:00]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.02 |
|
Non-Institutional Investors |
0.02 |
|
Retail Individual Investors (RIIs) |
0.14 |
|
Employees |
0.90 |
|
Total |
0.04 |
The company will not receive any proceeds, as the IPO is entirely an OFS (offer for sale); instead, they will be directly allocated to the selling shareholders.
WeWork India is a leading provider of flexible workspace solutions and operates as the exclusive franchisee of the globally recognised WeWork brand in the Indian market. Launched in 2017, the company has scaled its presence and consistently held the top position in terms of total revenue in the flexible workspace sector over the past three fiscal years.?
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.?
To read the RA disclaimer, please click here.